Brukinsa (zanubrutinib) prior authorization for oncology indications
Defines Cigna's prior authorization requirements and coverage criteria for Brukinsa (zanubrutinib capsules and tablets) for FDA‑approved oncology indications and select evidence‑supported uses for adults.
Tablet formulation was added to the policy and criteria.
A new FDA‑approved indication: follicular lymphoma in combination with obinutuzumab after two or more lines of systemic therapy with associated approval criteria.
Mantle cell lymphoma criteria expanded to include use in combination with rituximab or as induction with venetoclax and obinutuzumab for TP53 mutation.
Hairy cell leukemia and primary CNS lymphoma added as other uses with supportive evidence with specific criteria.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.